
Christine Johnston warns a thin biosimilar pipeline keeps specialty costs high and slows innovation and urges payers to check their PBM’s top 25 drugs.
Dimethyl fumarate is an investigational drug being studied for the treatment of relapsing-remitting multiple sclerosis (RRMS).






